^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Androgen receptor degrader

    Related drugs:
    1d
    A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer (clinicaltrials.gov)
    P1, N=15, Recruiting, Novartis Pharmaceuticals | Trial completion date: Jun 2027 --> Jan 2027 | Trial primary completion date: Jun 2027 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    luxdegalutamide (ARV-766)
    25d
    A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer (clinicaltrials.gov)
    P1/2, N=212, Recruiting, Qilu Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    enzalutamide • abiraterone acetate • MHB088C
    1m
    Phase 2 trial of ARPI to AR-degrader (BMS-986365) switch for suboptimal PSA-response in mCSPC (eARly-SWITCH). (2025-523672-23-00)
    P1/2, N=42, Not yet recruiting, UroTrials GmbH, AIO-Studien gGmbH
    New P1/2 trial
    2ms
    ANDROMEDA: A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs (clinicaltrials.gov)
    P1/2, N=300, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    saruparib (AZD5305)
    2ms
    An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) (clinicaltrials.gov)
    P2, N=150, Recruiting, Novartis Pharmaceuticals
    Trial initiation date
    |
    enzalutamide • abiraterone acetate • luxdegalutamide (ARV-766)
    2ms
    A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P2, N=138, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Nov 2028 --> May 2028 | Trial primary completion date: Jan 2028 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • luxdegalutamide (ARV-766)
    2ms
    An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) (clinicaltrials.gov)
    P1/2, N=188, Recruiting, Novartis Pharmaceuticals
    Trial initiation date
    |
    tulmimetostat (DZR123) • luxdegalutamide (ARV-766)
    3ms
    Mechanism and therapeutic significance of ARV-110 combined with a PDGFR inhibitor for the induction of apoptosis in castration-resistant prostate cancer cells through the ROS/JNK pathway. (PubMed, Cell Death Dis)
    The combination of ARV-110 and ponatinib exerted a significant inhibitory and synergistic effect on CRPC cells. Additionally, the substantial accumulation of reactive oxygen species induced by the combination strategy was related to the joint downregulation of catalase by the two drugs through different mechanisms. In conclusion, this study described a new strategy for the treatment of CRPC and clarified the molecular mechanisms of the combination strategy, providing a new theoretical basis for the precision treatment of CRPC.
    Journal
    |
    PDGFA (Platelet Derived Growth Factor Subunit A) • CAT (Catalase)
    |
    Iclusig (ponatinib) • bavdegalutamide (ARV-110)
    3ms
    A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P2, N=134, Active, not recruiting, Novartis Pharmaceuticals
    Trial initiation date
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • luxdegalutamide (ARV-766)
    3ms
    High-resolution functional mapping of androgen receptor variants. (PubMed, Nat Biomed Eng)
    This mapping identified 755 new non-functional AR variants and revealed 225 and 40 new variants resistant to enzalutamide and bavdegalutamide, an AR degrader, respectively. Our findings also enabled prognosis prediction for patients with prostate cancer based on AR mutation profiles. The broader implications of the study include improved androgen insensitivity syndrome diagnosis, better prostate cancer prognosis prediction and precision treatments for patients with prostate cancer.
    Journal
    |
    AR (Androgen receptor)
    |
    enzalutamide • bavdegalutamide (ARV-110)
    3ms
    A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P2, N=130, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • luxdegalutamide (ARV-766)
    3ms
    D7270C00001: A trial to learn how safe AZD9750 is and how well it works in people with metastatic prostate cancer when given with or without other anticancer drugs (2024-516976-14-00)
    P1/2, N=52, Not yet recruiting, AstraZeneca AB
    New P1/2 trial
    |
    saruparib (AZD5305)